Federal Register / Vol. 75, No. 112 / Friday, June 11, 2010 / Notices 33315 

Therefore, in accordance with 5 CFR 

1320.3(c), the reporting requirements in 

this notice are not defined as 

information collection requirements. 

(Catalog of Federal Domestic Assistance 

Program No. 93.773, Medicare—Hospital 

Insurance; Program No. 93.774, Medicare— 

Supplementary Medical Insurance, and 

Program No. 93.778, Medical Assistance 

Program) 

Dated: June 3, 2010. 

Marilyn Tavenner, 

Acting Administrator and Chief Operating 

Officer, Centers for Medicare & Medicaid 

Services. 

[FR Doc. 2010–14098 Filed 6–10–10; 8:45 am] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Notice of Meeting 

In accordance with section 10(d) of 

the Federal Advisory Committee Act (5 

U.S.C., Appendix 2), announcement is 

made of a Health Care Policy and 

Research Special Emphasis Panel (SEP) 

meeting. 

A Special Emphasis Panel is a group 

of experts in fields related to health care 

research who are invited by the Agency 

for Healthcare Research and Quality 

(AF[RQ), and agree to be available, to 

conduct on an as needed basis, 

scientific reviews of applications for 

AHRQ support. Individual members of 

the Panel do not attend regularlyscheduled meetings and do not serve for 

fixed terms or a long period of time. 

Rather, they are asked to participate in 

particular review meetings which 

require their type of expertise. 

Substantial segments of the upcoming 

SEP meeting listed below will be closed 

to the public in accordance with the 

Federal Advisory Committee Act, 

section 10(d) of 5 U.S.C., Appendix 2 

and 5 U.S.C. 552b(c)(6). Grant 

applications for the OS ARRA: 

Clinically-Enhanced State Data for 

Analysis for CE Impact (R01) 

applications are to be reviewed and 

discussed at this meeting. These 

discussions are likely to reveal personal 

information concerning individuals 

associated with the applications. This 

information is exempt from mandatory 

disclosure under the above-cited 

statutes. 

SEP Meeting on: OS ARRA: 

Clinically-Enhanced State Data for 

Analysis for CE Impact (R01). 

Date: July 2, 2010. (Open on July 2 

from 8 a.m. to 8:15 a.m. and closed for 

the remainder of the meeting.) 

Place: Hyatt Regency Bethesda Hotel, 

7400 Wisconsin Avenue, 1 Bethesda 

Metro Center, Conference Room TBD, 

Bethesda, MD 20814. 

Contact Person: Anyone wishing to 

obtain a roster of members, agenda or 

minutes of the non-confidential portions 

of this meeting should contact Mrs. 

Bonnie Campbell, Committee 

Management Officer, Office of 

Extramural Research, Education and 

Priority Populations, AHRQ, 540 

Gaither Road, Room 2038, Rockville, 

Maryland 20850, Telephone (301) 427– 

1554. 

Agenda items for this meeting are 

subject to change as priorities dictate. 

Dated: May 27, 2010. 

Carolyn M. Clancy, 

Director. 

[FR Doc. 2010–13982 Filed 6–10–10; 8:45 am] 

BILLING CODE 4160–90–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP): Research 2 

Practice and Construction Research 

Application, Request for Application 

(RFA) OH09–001, Initial Review 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC), 

announces the aforementioned meeting: 

Time and Date: 3 a.m.–5 p.m., July 7, 2010 

(Closed). 

Place: National Institute for Occupational 

Safety and Health (NIOSH), 2400 Century 

Parkway, NE., Fourth Floor, Atlanta, Georgia 

30345, Telephone: (404) 498–2530. 

Status: The meeting will be closed to the 

public in accordance with provisions set 

forth in Section 552b(c)(4) and (6), Title 5, 

U.S.C., and the Determination of the Director, 

Management Analysis and Services Office, 

CDC, pursuant to Section 10(d) of Public Law 

92–463. 

Matters To Be Discussed: The meeting will 

include the initial review, discussion, and 

evaluation of applications received in 

response to ‘‘Research 2 Practice and 

Construction Research Application, RFA 

OH09–001’’. 

Agenda items are subject to change as 

priorities dictate. 

Contact Person for More Information: Chris 

Langub, PhD, Scientific Review Officer, 

NIOSH, CDC, 2400 Century Center, Atlanta, 

GA 30333, Telephone: (404) 498–2543. 

The Director, Management Analysis and 

Services Office has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities for 

both CDC and the Agency for Toxic 

Substances and Disease Registry. 

Dated: June 4, 2010. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2010–14074 Filed 6–10–10; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0268] 

Dental Products Panel of the Medical 

Devices Advisory Committee; Notice of 

Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Dental Products 

Panel of the Medical Devices Advisory 

Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on December 14 and 15, 2010, from 

8 a.m. to 6 p.m. 

Location: Holiday Inn-Gaithersburg, 

Main Ballroom, 2 Montgomery Village 

Ave., Gaithersburg, MD 20879. 

Contact Person: Olga I. Claudio, Food 

and Drug Administration, Center for 

Devices and Radiological Health, WO 

66, rm. 1553, Silver Spring, MD 20993– 

0002, 301–796–7608 or FDA Advisory 

Committee Information Line, 1–800– 

741–8138 (301–443–0572 in the 

Washington, DC area), code 301–451– 

2518. Please call the Information Line 

for up-to-date information on this 

meeting. A notice in the Federal 

Register about last minute modifications 

that impact a previously announced 

advisory committee meeting cannot 

always be published quickly enough to 

provide timely notice. Therefore, you 

should always check the agency’s Web 

site and call the appropriate advisory 

committee hot line/phone line to learn 

about possible modifications before 

coming to the meeting. 

Comments: FDA is opening a docket 

for public comment on this document. 

WReier-Aviles on DSKGBLS3C1PROD with NOTICES